|
Protocol |
Drug/Test/Device |
Indication |
Study Sponsor |
Phase |
# of patients enrolled |
Drug/Device approved by FDA/Results? |
Study published? |
|
|
Targretin |
Kaposi's Sarcoma |
Ligand Pharmaceuticals |
II |
12 |
No |
No |
|
|
Panretin (alitretinoin) gel |
Kaposi's Sarcoma |
Ligand Pharmaceuticals |
III |
24 |
Yes |
Yes |
|
|
Comprehensive Patient and Caregiver HIV Education |
HIV |
Glaxo Wellcome |
N/A |
10 |
N/A |
Yes |
|
|
Immediate versus delayed phenotype |
HIV Resistance Testing |
Virco/Glaxo Wellcome |
N/A |
26 |
Yes |
Yes |
|
|
Phenotype |
HIV Resistance Testing |
Virco/Glaxo Wellcome |
N/A |
13 |
Yes |
Yes |
|
|
Genetic antisense vector |
HIV |
Enzo Therapeutics |
I/II |
5 |
Ongoing |
Yes |
|
1330-IMIQ |
Aldara (imiquimod) |
Genital herpes |
3M Pharmaceuticals |
II |
29 |
No |
No |
|
|
IM862 |
Kaposi's Sarcoma |
Cytran |
III |
8 |
No |
No |
|
|
Valtrex |
Genital herpes -- prevention of transmission among
serodiscordant couples |
Glaxo Wellcome |
IV |
2 |
Phase IV study -- outcome favorable |
Yes |
|
|
Valtrex |
Genital herpes -- prevention of outbreaks in HIV
positive patients |
Glaxo Wellcome |
IV |
12 |
Phase IV study -- outcome favorable |
Yes |
|
|
ALG 889 |
HIV |
Allergene |
I |
17 |
Phase I study |
No |
|
|
Panretin (alitretinoin) gel |
Kaposi's sarcoma -- concomitant with Doxil therapy |
Ligand Pharmaceuticals |
IV |
4 |
Favorable results |
Yes |
|
|
Panretin (alitretinoin) gel |
Kaposi's sarcoma -- classical KS |
Ligand Pharmaceuticals |
IV |
2 |
Phase IV study -- outcome favorable |
No |
|
|
Resiquimod cream 1411- RESI |
Genital herpes |
3M Pharmaceuticals |
II |
17 |
No |
Yes |
|
|
Resiqumod cream 1423 RESI |
Genital herpes |
3M Pharmaceuticals |
III |
9 |
No |
No |
|
|
Resiquimod cream 1452 RESI |
Genital herpes |
3M Pharmaceuticals |
III |
2 |
No |
No |
|
|
Procrit |
HIV related anemia |
Ortho Biotech |
IV |
0 |
? |
No |
|
|
Atazanavir |
HIV |
Bristol Myers Squibb |
Expanded Access |
5 |
Yes |
No |
|
|
Avandia |
Psoriasis |
Glaxo Smith Kline |
III |
1 |
No |
No |
|
|
Famvir US07 |
Prophylaxis for genital herpes |
Novartis |
IV |
16 |
Yes |
Yes |
|
|
Famvir 2403 |
Cold sores |
Novartis |
IV |
18 |
Yes |
Yes |
|
|
New Fill |
HIV associated facial wasting |
Dermik (manufacturer) |
II |
24 |
Yes |
Yes |
|
TMC114-C202 |
TMC114 |
HIV |
Tibotec |
II |
18 |
Yes |
Yes |
|
TMC114-C215 |
TMC114 |
HIV |
Tibotec |
II |
10 |
Yes |
Yes |
|
TMC125-C216 (Duet) |
TMC114/TMC125 |
HIV |
Tibotec |
III |
5 |
Ongoing |
|
|
ML 19712 (BLQ) |
T20/TMC114 |
HIV |
Roche |
IV |
4 |
Unknown |
|
|
CFAM810A2308 |
Famvir vs. Valtrex |
Genital Herpes |
Novartis |
IV |
22 |
Ongoing |
|